NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

BriaCell Therapeutics Corp. (BCTX) Stock Analysis

BriaCell Therapeutics Corp. (BCTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

BCTX

$3.57

+$0.04 (+1.13%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BCTX with… →

BCTX Key Statistics

As of Sep 4, 2026
Trading
Open
$3.48
Previous Close
$3.53
Day's Range
3.46–3.60
52-Week Range
2.60–14.68
Volume
108.26K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.53
Valuation
Market Cap
$31.06M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.84
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$4.79M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
8.70M
1-Year Return
−53.76%
Dividend and dates
Avg Volume
295.89K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BCTX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−49.79%
2025+26.96%
2024−90.43%
2023+33.87%
2022−47.22%
2021+98.56%
2020−53.67%
2019−40.00%
2018−50.00%
2017−33.33%
2016 (partial year)−16.67%

As of September 4, 2026.

BCTX Revenue and Earnings by Fiscal Year

FY ends July
Fiscal yearRevenueNet incomeNet margin
2024$0.00−$4.79M—
2023$0.00−$20.30M—
2022$0.00−$26.84M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2024$0.00—−$33.33M−$4.79M—
2023$0.00—−$23.27M−$20.30M—
2022$0.00—−$15.29M−$26.84M—

Annual figures as reported, in the company's reporting currency. As of July 31, 2024.

BCTX Valuation vs Biotechnology Median

Median of 654 stocks
MetricBCTXBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 654 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

BriaCell Therapeutics Corp. (BCTX) carries a market capitalisation of $31.06M. It is classified in the Biotechnology industry, within the Healthcare sector.

The most recent close on file for BCTX is $3.57, dated September 4, 2026. That is +$0.04 (+1.13%) against the previous close. The 52-week range on file runs from $2.60 to $14.68. The latest close sits 37.31% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2024, shows revenue of $0.00. The same year closed with a net loss of $4.79M. The reported profit margin is 0%. Trailing earnings per share are −0.84.

Across the 3 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2024. Of those 3 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is 1.53. Annualized volatility over the trailing 10 years is 488.29%. The trailing one-year price return is −53.76%. Across 10 years the annualized return works out at −39.79%.

Growth & Income

No dividend is on file for BCTX.

Across the complete calendar years on file, 2021 returned +98.56% and 2024 returned −90.43%. Of the 9 complete calendar years on file, 3 finished higher. So far in 2026 the price is −49.79%.

Peer Comparison

BriaCell Therapeutics Corp. (BCTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
BriaCell Therapeutics Corp. BCTX $31.06M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 31.8
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 39.4

The Biotechnology industry average P/E ratio is 12.9x. BriaCell Therapeutics Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Visit website →